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The South African Childhood Asthma Working Group (SACAWG), 
a subcommittee of the Allergy Society of South Africa (ALLSA), 
first published its guideline for the management of chronic asthma 
in children and adolescents in 1992, followed by revisions in 1994,[1] 
2000[2] and 2009.[3] In the interim, there have been a number of key 
changes in the diagnostic criteria (particularly in young children, 
assessment of asthma control, management principles, new drugs 
and new drug-delivery devices). 
Pharmacotherapy is the cornerstone of asthma management. 
Selection of medication and delivery devices has to meet the patients’ 
needs and characteristics. Periodic assessment of asthma control and 
review of management are critical to gain control of the disease and 
limit medication side-effects. 
Methods
SACAWG reconvened in January 2017 with 6 task groups, each headed 
by a leader (Appendix A), constituting the editorial committee on 
assessment of asthma epidemiology, diagnosis, control, treatments, 
novel treatments and self-management plans. The asthma medication 
task groups were charged with the responsibility of reviewing the 
available scientific literature and assigning evidence levels according 
to the methodology used in current guideline documents. PubMed 
and Google Scholar searches were done to review the current level of 
evidence since the publication of the previous guideline.[3] The level of 
evidence and key recommendations were graded (Appendix B) according 
to the Grades of Recommendation Assessment, Development and 
Evaluation (GRADE) system. After completion of each sub-section, 
it was sent to the entire working group for review, comment and 
revision. Any disagreements or inconsistencies were dealt with via 
round robin, with a majority recommendation based on the evidence 
if there was disagreement.
Assessment of severity to initiate 
therapy 
The method of assessment conforms to international assessment 
criteria. The assessment of severity is used to assign a child to a 
particular treatment group as a starting point. This assessment refers 
to a child’s symptoms and lung function (peak expiratory flow (PEF) 
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or forced expiratory flow in 1 second (FEV1)) between acute episodes 
if they are not receiving long-term therapy (Table 1). Severity can 
also be measured once asthma control is achieved by the step of care 
(i.e. various medications) required to maintain control. One or more 
features must be present to assign a severity grading to the most 
severe grade in which any feature occurs.
Principles of medication
When selecting medication for an asthmatic patient, the following 
principles apply: regular anti-inflammatory medication is indicated 
for persistent asthma, but inhaled therapy is preferable, especially 
inhaled bronchodilators and inhaled steroids. 
Drugs are classified as:
• Relievers (bronchodilators) for acute relief from symptoms, includ-
ing inhaled short-acting beta2-agonists (SABAs) (evidence level I) 
and anticholinergics. Short-acting xanthines are not recommended 
in the maintenance treatment of asthma. Anticholinergics are less 
potent, have a slower onset of action (30 - 60 minutes) and can be 
used during exacerbations. 
• Controllers (anti-inflammatory drugs) for long-term control may 
modify airway inflammation that is characteristic of asthma. 
Inhaled corticosteroids (ICSs) are the most effective controller 
therapy for asthma (evidence level I). Leukotriene receptor 
antagonists (LTRAs) are anti-inflammatories that exert their 
effects via different pathways than ICSs. Long-acting beta2-
agonists (LABAs) have weak anti-inflammatory effects. Slow-
release theophyllines also have weak anti-inflammatory effects at 
lower doses than those required for bronchodilation.
A number of different ICS preparations are available in South 
Africa (SA) (Tables 2 and 3). ICSs are usually administered twice 
daily, but budesonide and ciclesonide (registered only for child-
ren >12 years old) are approved for once-daily use in children 
with mild asthma. Most children >5 years of age are controlled on 
low daily doses of ICSs (100 - 200 µg budesonide or equivalent). 
Wheezing caused by viral infections is very common in child-
ren ˂2 years of age and often resolves spontaneously or remits 
with increasing age. ICSs should only be used if symptoms are 
particularly troublesome, and if there is a need for admission 
and oxygen therapy, with a clear response to treatment. Most 
importantly, the administration of ICSs should be discontinued if 
there is no response or a poor response.
LABAs should only be used in combination with an ICS. LABAs are 
primarily indicated as add-on therapy in children >5 years of age, 
whose asthma is not controlled by moderate doses of ICSs (evidence 
level II) (Table 4).
LTRAs have a rapid onset of action (1 - 3 hours) and are taken 
once a day. They are available in 5 mg tablets, 4 mg chewable tablets 
and 4 mg oral granule formulations. Because of easy administration 
(compared with inhaler devices) and once-daily dosing, patients 
are often adherent to LTRAs only. It should be noted and explained 
to parents that LTRAs are not the preferred first-line treatment for 
asthma. LTRAs have been shown to be inferior to ICSs with regard 
Table 1. Classification of asthma severity based on symptoms and lung function (presenting for the first time without treatment)
Classification Mild intermittent Mild persistent Moderate persistent Severe persistent
Symptoms ≤2/week >2/week Daily Continual 
Night-time symptoms ≤1/month >1/month >1/week Frequent
PEF (predicted), % ≥80 ≥80 >60 - ≤80 ≤60
PEFR variability, %* <20 20 - 30 >30 >30
PEF = peak expiratory flow; PEFR = peak expiratory flow rate.
*Applicable to children >5 years old.
Table 2. Preferred low-dose ICS in children ˂5 years old* 
ICS
Total daily inhaled  
dose, µg
Beclomethasone dipropionate (HFA) 100
Budesonide (pMDI and spacer)†
Budesonide (nebulised)†
200
500
Fluticasone propionate (HFA) 100
ICS = inhaled corticosteroid; HFA = hydrofluoroalkane; pMDI = pressurised metered-dose 
inhaler.
*Adapted from Global Initiative for Asthma.[4] 
†Most preparations are registered for twice-daily use, except budesonide, which may be     
administered once daily.
Table 3. Estimated equipotent daily dosage of ICS for children 6 - 11 years old 
Drug Low daily dose, µg Medium daily dose, µg High daily dose, µg
Beclomethasone dipropionate CFC 100 - 200 200 - 400 >400
Budesonide DPI 100 - 200 200 - 400 >400
Ciclesonide HFA* 80 80 - 160 >160
Fluticasone propionate HFA† 100 - 200 200 - 500 >500
Mometasone furoate 110 220 - <440 >440
Adolescents (≥12 years old)
Beclomethasone dipropionate HFA 100 - 200 >200 - 400 >400
Budesonide DPI 200 - 400 >400 - 800 >800
Ciclesonide HFA 80 - 160 >160 - 320 >320
Fluticasone propionate HFA† 100 - 250 >250 - 500 >500
Fluticasone furoate‡ - - -
Mometasone furoate 110 - 220 >220 - 440 >440
CFC = chlorofluorocarbon; DPI = dry powder inhaler; HFA = hydrofluoroalkane. 
*Ciclesonide is registered for children ≥12 years old.
† May be used at half the dose of budesonide equivalent.
‡Equivalent doses unknown. 
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to symptom improvement, exacerbation decrease and hospitalisation 
frequency in the treatment of asthma in the preschool child. This 
medication may be used as add-on therapy in children >5 years of age, 
whose asthma is insufficiently controlled by low doses of ICSs (evidence 
level II), or as alternative first-line therapy to ICSs for episodic or mild 
persistent asthma in children ˂5 years old (evidence level II). 
Theophylline may be used as add-on therapy in more severe 
asthma that is not controlled with ICSs in children >12 years of age 
and in adults (evidence level IV), but safety concerns preclude its 
recommendation.
Oral corticosteroids should only be used for acute asthma 
exacerbations, preferably only in hospitalised patients and for a 
maximum of 3 days at 0.5 - 1 mg/kg/dose of prednisone given once 
daily. For children ˂5 years old, these are only recommended in 
exacerbations that require hospitalisation.
Routes of administration
Inhaled medications
Inhaled therapy is the cornerstone of asthma treatment for all 
children. Most children can be taught to use inhaled therapy 
effectively. Different age groups require different inhaler devices 
together with a pressurised metered-dose inhaler (pMDI) with or 
without a holding chamber (spacer). The alternative is a dry powder 
metered-dose inhaler (DPI) (Box 1). Considerations when choosing 
an inhaler device include the efficacy of drug delivery, cost, safety, 
ease of use, convenience and efficacy in a specific age group.[5] A 
pMDI with holding chamber (spacer) is preferable to nebulised 
therapy owing to convenience, more effective lung deposition, fewer 
side-effects and lower cost.[6-8] The technique for each device type 
varies, has to be correct for optimal drug delivery and should be 
checked at each visit (Box 2). 
Valved holding chamber (spacer)
Valved holding chambers allow inhalation at a normal respiratory 
rhythm even without synchronising actuation and inhalation, thus 
increasing inhalation efficiency. Spacers also retain large drug 
particles that would otherwise be deposited in the oropharynx. 
This reduces oropharyngeal side-effects, systemic absorption 
and bio-availability of inhaled drug. It is especially important 
for ICSs with first-pass metabolism, such as beclomethasone and 
budesonide. 
Nebulisers
A pMDI with a spacer is as effective as, or more effective than, 
nebulised treatment for acute, severe asthma exacerbation.[8,9] 
Nebulisers have imprecise dosing, are expensive and waste large 
amounts of drug into the surrounding air. For home use, nebulisers 
are discouraged; they should be restricted to cases where oxygen 
administration is necessary and available (evidence level I).
Dry powder inhaler 
A DPI is a breath-actuated device containing micronised drug 
particles with a mass median aerodynamic diameter of ˂5 µm.[10,11] 
DPI devices eliminate the requirement for propellants, as well as 
for co-ordination between inhalation and device actuation. The 
dis advan tage of DPIs is the high inspiratory flow rates (30 - 120 L/
min)  that are required to aerosolise the drug.[11,12] In one study, the 
age at which most children who were inexperienced in the use of a 
DPI could generate a peak inspiratory flow rate of ≥30  L/min  was 
4 years, and the age at which most children could generate a peak 
inspiratory flow rate of ≥60 L/min was 9 years.[12] Furthermore, the 
rapid inhalation required to ensure optimal lung deposition might be 
confusing for children who use both an MDI and a DPI. It should be 
noted that equivalent doses for these devices also differ.
Table 4. Combination products available in South Africa*
Combination Device Dose, µg
Fluticasone propionate/
salmeterol
DPI (Accuhaler) 100/50
250/50
500/50
Fluticasone propionate/
salmeterol
pMDI 50/25
125/25
250/25
Budesonide/formoterol 
fumarate
pMDI 80/4.5
160/4.5
Budesonide/formoterol 
fumarate
DPI (Turbuhaler) 80/4.5
160/4.5
320/9
Fluticasone furoate/
vilanterol†
pMDI 100/25
Mometasone furoate/
formoterol fumarate
pMDI 100/5
Mometasone furoate/ 
formoterol fumarate
pMDI CFC free 100/5
200/5
pMDI = pressurised metered-dose inhaler; DPI = dry powder inhaler;  
CFC = chlorofluorocarbon.
*Adapted from Global Initiative for Asthma[4] and Hossny et al.[5]
†Indicated only for children ≥12 years old. 
Box 1. Choice of inhaler device for children
Age group, years Preferred device
˂4 pMDI and spacer with face mask 
4 - 6 pMDI and spacer with mouthpiece
>6 Dry powder inhaler, or pMDI with spacer 
and mouthpiece or breath-actuated pMDI 
pMDI = pressurised metered-dose inhaler.
Box 2. Correct use of pressurised metered-dose inhaler and 
holding chamber (spacer)
Assemble spacer, remove mouthpiece cover from the pMDI, and 
attach MDI
Shake canister vigorously for 5 s, then hold assembled canister-
spacer/chamber in a horizontal position
Breathe out normally
Place mouthpiece of spacer/chamber into mouth and close lips 
around mouthpiece*
At the start of the next inhalation, actuate the pMDI 
Keep inhaling deeply and slowly through your mouth. If you 
hear a whistling sound from the chamber, slow down the rate of 
inhalation
Hold your breath for 5 - 10 s. Then breathe out slowly and gently†
Wait 15 - 30 s before you give the second puff, if required. Shake 
the inhaler again before the second puff
If the inhaler is a steroid medicine, rinse out your mouth, gargle, 
and spit out the water
Remove the pMDI from spacer/chamber and replace the 
mouthpiece cover
pMDI = pressurised metered-dose inhaler.
*If the spacer has a facemask, hold the latter snugly over the child’s mouth and nose.
†In a young child who cannot follow instructions, press the pMDI at the start of a slow   
breath in and keep mask firmly in place for 5 - 6 breaths.
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Treatment options
Before stepping up of treatment, symptom control, steroid side-
effects and comorbid conditions (e.g. allergic rhinitis) must be 
assessed. Ensure adequate patient education (e.g. inhaler skills, 
adherence and written asthma action plan). Assess environmental 
exposure to allergens and irritants, especially tobacco smoke. 
Consider the possibility of an alternative diagnosis, poor adherence 
to treatment or incorrect inhaler technique. Do not step up treat-
ment unless the abovementioned problems have been addressed 
(Tables 5 and 6).
Step 1: Short-acting beta2-agonist as needed
In the case of mild symptoms (not requiring oral corticosteroids 
and hospital admission with supplemental oxygen), a SABA with a 
dedicated spacer device, facemask and an adequate technique are 
indicated. This treatment is reserved for infrequent symptoms and 
will not prevent future exacerbations. 
ICSs should be considered for patients with any of the following 
asthma-related features:[14-16] 
• an asthma attack in the past 2 years, requiring the use of 
broncho dilators and systemic steroids
• using inhaled SABAs ≥3 times a week 
• symptomatic ≥3 times a week
• nocturnal waking ≥1 times a week.
Step 2: Low-dose controller medication and as-needed reliever 
medication
In all children the preferred option is regular low-dose ICSs, which 
are the most effective preventer drugs for adolescents and older 
children for achieving overall treatment goals (evidence level I).[13-15] 
Treatment with low-dose ICSs reduces asthma symptoms, improves 
lung function and quality of life, and reduces the risk of exacerbations, 
asthma-related hospitalisations and death (evidence level I).[13,17,18]
Alternative options
In young children with recurrent viral-induced wheezing, regular 
LTRAs improve some asthma outcomes compared with placebo, but 
do not reduce the frequency of hospitalisation, courses of prednisone, 
or number of symptom-free days (evidence level I). As an alternative, 
LTRAs have some beneficial clinical effects and may be used as initial 
controller treatment in children unable or unwilling to use ICSs, for 
patients who experience intolerable side-effects from ICSs or for 
those with concomitant allergic rhinitis (evidence level II).[19-23]
Intermittent inhaled corticosteroids
For patients with purely seasonal allergic asthma, with no intercurrent 
asthma symptoms, ICSs should be started immediately when 
symptoms commence and continued for 4 weeks after the relevant 
pollen season ends (evidence level IV). Daily ICSs are superior 
to intermittent ICSs in several indicators of lung function, airway 
inflammation, asthma control and reliever use. The strength of the 
evidence means that, currently, equivalence cannot be assumed 
between the two options and therefore it is recommended to use daily 
ICSs (evidence level I).[24]
Step 3: Add an additional controller and as-needed reliever 
medication
A poor response to low-dose ICSs should be escalated to medium-
dose ICSs with as-needed SABAs as the preferred treatment option. 
In children ˂6 years of age an alternative treatment is medium-
dose ICSs or the addition of an LTRA. As an alternative choice, a 
low-dose ICS/LABA combination with an as-needed SABA can 
be administered to children >6 years old. To date, evidence shows 
that the outcomes of these two treatments are similar.[25,26] However, 
meta-analyses demonstrated a trend towards increased risk of 
exacerbations requiring rescue therapy and hospitalisation with ICS/
LABA treatment in children ˂12 years compared with medium-
dose ICSs (evidence level I).[24-26] Based on this, it is currently 
recommended to escalate therapy to medium-dose ICSs as the 
preferred choice in this age group. 
For children ≥12 years of age, the first choice is adding a LABA to a 
low-dose ICS. There are two strategies for doing this. The traditional 
approach of combination ICS/LABA therapy with as-needed SABA 
reliever therapy is well proven to improve asthma control rather 
than ICSs alone (evidence level I).[27] The more recent approach of 
ICS/formoterol maintenance and reliever therapy (or single-inhaler 
therapy) may, however, be preferable to traditional fixed-dose ICS/
LABA therapy. Studies comparing the two demonstrate a reduced daily 
Table 6. Asthma treatment options for children ≥6 years old
Step 1
Intermittent reliever therapy SABA as needed 
Step 2
 Low-dose controller and  
as-needed reliever medication
Low-dose ICS
Step 3
 Additional controller and 
as-needed reliever medication
Low-dose ICS/LABA 
combination therapy (first 
choice)
Medium-dose ICS (second 
choice)
Step 4
 ≥2 controllers and as-needed 
reliever medication
Low-dose ICS/LABA and 
LTRA
Medium-dose ICS and LABA
Tiotropium (>12 years of age) 
– add to step 3 drugs
Theophylline (>12 years of age)
Step 5
 Refer to specialist (paediatrician, paediatric allergologist or 
paediatric pulmonologist)
SABA = short-acting beta2-agonist; ICS = inhaled corticosteroid; LABA = long-acting 
beta2-agonist; LTRA = leukotriene receptor antagonist.
Table 5. Asthma treatment options for children 2 - 5 years of age
Step 1
 Intermittent reliever therapy SABA as needed
Step 2
 Low-dose controller and 
as-needed reliever medication
Low-dose ICS
Intermittent ICS (second 
choice if seasonal symptoms)
LTRA
Step 3
 Additional controller and 
as-needed reliever medication
Medium-dose ICS
Low-dose ICS and LTRA
Step 4
 Refer to specialist (paediatrician, paediatric allergologist or 
paediatric pulmonologist)
SABA = short-acting beta2-agonist; ICS = inhaled corticosteroid; LTRA = leukotriene 
receptor antagonist.
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dose of ICS and a reduced exacerbation rate requiring oral steroids or 
hospitalisation in the former group (evidence level I).[27-31] Of particular 
importance is that in any age group LABAs should never be used alone 
and should only be used in combination with an ICS.
The addition of slow-release theophylline to a low-dose ICS has 
a similar effect as an increase from low- to medium/high-dose ICS 
(evidence level II).[32] 
Step 4: Two or more controllers and as-needed reliever medication
Other options in this group are switching to high-dose ICSs and 
adding a second controller, or adding a third controller to a failing 
medium-dose ICS/LABA regimen. Tiotropium administered by 
means of a mist inhaler has been demonstrated to improve asthma 
control in patients who receive medium-dose ICS/LABA therapy 
and was non-inferior to adding salmeterol to medium/high-dose 
steroid monotherapy in severe asthma (evidence level I).[33] Similarly, 
the addition of an LTRA[34-37] (evidence level II) or slow-release 
theophylline[70] (evidence level II) is efficacious in improving asthma 
control in severe asthmatics.
Of note is that ICSs have a relatively flat dose-response curve. 
The main benefits appear to be gained from the use of low- to 
medium-dose steroids. An increase to high-dose steroids confers 
little advantage, at the expense of greater side-effects (evidence 
level I).[38,39] Hence, it is generally preferable to add a second or third 
controller to a failing regimen than increasing the steroid burden.
Step 5: Refer
All children with severe asthma who fail appropriate therapy should 
be referred to a paediatrician, paediatric allergologist or paediatric 
pulmonologist for further management, also to confirm the diagnosis 
and exclude aggravating comorbidities. 
Stepping-down treatment
Stepping-down treatment should be considered once good asthma 
control has been achieved and maintained for 3 months and lung 
function has reached a plateau (evidence level IV). Any step-
down treatment depends on patient characteristics, as only a few 
step-down studies have been performed in children. Approach 
each step as a therapeutic trial. Provide clear instructions and an 
asthma action plan. Monitor symptoms and/or PEF and schedule a 
follow-up visit. Stepping down ICS doses by 25 - 50% at 3-month 
intervals is feasible and safe for most patients (evidence level I). 
When stepping down to once-daily dosing, it should preferably be a 
morning dose. Box 3 summarises step-down strategies for different 
controller treatments.
Conclusion
To ensure a good response from treatment and adherence, the type 
of medication, device and checking of technique are critical. Stepping 
up of therapy should be done only after ensuring good adherence 
and technique. Once therapeutic response is achieved, medication 
has to be stepped down to improve ease of medication use and avoid 
unnecessary side-effects.
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Box 3. Options for stepping-down treatment in well-controlled asthma* 
Current step Current medication and dose Options for stepping down Evidence level
Step 4 Moderate- to high-dose ICS/LABA
Medium-dose ICS/formoterol as 
maintenance and reliever
High-dose ICS and second controller
Continue ICS/LABA with 50% reduction in ICS 
component
Discontinuation of LABA is more likely to lead to 
deterioration[40]
Reduce maintenance ICS/formoterol to low dose, 
continue as needed with low-dose ICS/formoterol 
reliever
Reduce ICS dose by 50% and continue 
controller[41] 
II
I
IV
II
Step 3 Low-dose ICS/LABA 
Low-dose ICS/formoterol as 
maintenance and reliever
Moderate- or high-dose ICS
Reduce ICS/LABA to once-daily dosing
Discontinuation of LABA is more likely to lead to 
deterioration[40]
Reduce maintenance ICS/formoterol dose to once 
daily and continue as needed with low-dose ICS/
formoterol reliever
Reduce ICS dose by 50%[41]
IV
I
III
I
Step 2 Low-dose ICS
Low-dose ICS or LTRA
Once-daily dosing (budesonide, ciclesonide, 
mometasone)
Consider stopping controller treatment if no 
symptoms for 6 - 12 months and no risk factors
I
IV
ICS = inhaled corticosteroid; LABA = long-acting beta2-agonist; LTRA = leukotriene receptor antagonist.
*Adapted from South African Childhood Asthma Working Group.[1]
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Appendix A. The SA Childhood Asthma Working Group (SACAWG)
Epidemiology: H Zar (leader), Western Cape; C Gray, Western Cape.
Diagnosis of asthma: R Masekela (leader), KwaZulu-Natal; S M Risenga, Limpopo; O P Kitchin, Gauteng; P Goussard, Western Cape.
Assessment of asthma control: R J Green (leader), Gauteng; A van Niekerk, Gauteng; D White, Gauteng; G Davis, Gauteng.
Pharmacotherapy: F E Kritzinger (leader), Western Cape; A Jeevanathrum, Gauteng; P de Waal, Free State; S Kling, Western Cape; A Vanker, 
Western Cape; T C Gray, Western Cape; J Morrison, Western Cape; A Puterman, Western Cape; E Zöllner, Western Cape; D Rhode, Western Cape.
Pharmacotherapy – other therapies: A I Manjra (leader), KwaZulu-Natal; P M Jeena, KwaZulu-Natal; V Naidoo, KwaZulu-Natal; 
M Annamalai, KwaZulu-Natal; A van Niekerk, Gauteng.
Self-management plans: M Levin (leader), Western Cape; S Emanuel, Western Cape; D Hawarden, Western Cape; H Katz, Gauteng.
Appendix B. Level of evidence 
IA   Evidence from meta-analysis and randomised controlled trials
IB Evidence from at least one randomised controlled trial
IIA Evidence from at least one controlled trial without randomisation
IIB Evidence from at least one or other quasi-experimental study
III Evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case-controlled studies
IV Evidence from expert committee reports, opinions or clinical experience of respected authorities
618       August 2018, Vol. 108, No. 8
CME
Appendix B. Grades of Recommendation Assessment, Development and Evaluation (GRADE) 
Level of 
recommendation Quality of evidence Definition
A High High-quality research very unlikely to change our confidence in the estimate effect based on 
level I evidence
B Moderate Moderate-quality evidence, where future research is likely to have an important impact 
on our confidence in the estimate effect. Based on level II evidence or extrapolated from 
recommendations from level I evidence
C Low Low-quality evidence, where future research is likely to have an important impact on our 
confidence in the estimate effect. Based on level III evidence or recommendations from level I 
and II evidence
D Very low Very-low-quality evidence, where the estimate effect is uncertain. Based on level IV evidence 
or recommendations from level I, II and III evidence
